PMID: 8471439Apr 1, 1993Paper

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

British Journal of Cancer
R P A'HernS R Ebbs

Abstract

The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in advanced breast cancer was assessed by performing an overview employing summary statistics derived from published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimens in which dox was replaced by one or more compounds. Trials were selected which published data on survival, time to treatment failure and response rate. This study suggests that dox confers advantages on all of these endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox.

Citations

Sep 8, 1998·Japanese Journal of Clinical Oncology·T Watanabe
Jun 14, 2000·Breast Cancer Research and Treatment·D W van ToornJ B Vermorke
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·G N HortobagyiL Asmar
Jun 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoA C Wolff
May 23, 2001·Breast Cancer Research and Treatment·E AlbaJ Miramón
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George P StathopoulosJohn G Stathopoulos
May 22, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph A SparanoAntonio C Wolff
Jan 5, 2002·Journal of the National Cancer Institute. Monographs·G N Hortobagyi
Sep 25, 2002·Drugs·Herbert G SayerKlaus Höffken
Apr 15, 2006·Expert Review of Anticancer Therapy·Ruth E BoardAndrew M Wardley
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maureen E TrudeauJean-Francois Pouliot
Apr 5, 2016·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Toshinori SasakiMitsuhiro Mizutani
May 20, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Deniz Tataroglu OzyukselerMahmut E Yıldırım
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoM J Egorin
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V ValeroG N Hortobagyi
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P AcklandUNKNOWN HEPI 013 study group
Feb 27, 2003·Breast Cancer Research and Treatment·David M LoeschNicholas J Robert
Mar 11, 2003·Statistics in Medicine·Sylvain Durrleman, Philip Chaikin
Jul 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David OsobaMaureen Murphy
Aug 10, 2005·Expert Opinion on Pharmacotherapy·Emer O HanrahanVicente Valero
Mar 24, 2007·Breast Cancer Research and Treatment·Armelle DufresneAimery De Gramont
Mar 21, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia CortazarRichard Pazdur
Dec 30, 2014·Frontiers in Oncology·Shuang Guo, Serena Wong
Feb 9, 2020·Cardiovascular Drugs and Therapy·Kerstin N Timm, Damian J Tyler
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M AndoN Katsumata
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GennariP F Conte
Sep 25, 2003·Breast Cancer Research and Treatment·Emilio EstebanUNKNOWN Grupo Oncológico del Norte de España
Dec 18, 2004·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Takashi IshikawaUNKNOWN Kanagawa Breast Cancer Treatment Society (KBCTS)
Jan 24, 2002·Breast Cancer Research and Treatment·M AiroldiV Recalenda
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoW C Wood
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J JassemUNKNOWN Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.